TABLE 3.
Characteristics of patients with colorectal cancer treated before and during the COVID‐19 pandemic
| Characteristic | Before COVID‐19 (N = 3569) | During COVID‐19 (N = 3198) | P b |
|---|---|---|---|
| Sex, male/female | 1947/1622 | 1789/1409 | .260 |
| Age, y | 72 (20–102) | 72 (24–98) | .136 c |
| BMI, kg/m2 | 21.9 (7.5–43.4) | 22.1 (8.3–63.9) | .049 c |
| ASA‐PS | .004 | ||
| ≤2 | 2963 (83.0%) | 2567 (80.3%) | |
| ≥3 | 606 (17.0%) | 631 (19.7%) | |
| Tumor location | .242 | ||
| Right side | 1297 (36.3%) | 1118 (35.0%) | |
| Left side | 2272 (63.7%) | 2080 (65.0%) | |
| Depth of tumor invasion | .025 | ||
| ≤T2 | 1022 (28.6%) | 838 (26.2%) | |
| ≥T3 | 2547 (71.4%) | 2360 (73.8%) | |
| Lymph node metastasis | .883 | ||
| Positive | 1512 (42.4%) | 1361 (42.6%) | |
| Negative | 2057 (57.6%) | 1837 (57.4%) | |
| Distant metastasis | .659 | ||
| Positive | 535 (15.0) | 492 (15.4) | |
| Negative | 3034 (85.0) | 2706 (84.6) | |
| Stage | .011 | ||
| ≤I | 959 (26.9%) | 773 (24.2%) | |
| ≥II | 2610 (73.1%) | 2425 (75.8%) | |
| Approach | <.001 d | ||
| Open | 449 (12.6%) | 366 (11.4%) | |
| Laparoscopic | 2803 (78.5%) | 2416 (75.6%) | |
| Robot‐assisted | 317 (8.9%) | 416 (13.0%) | |
| Primary tumor resection | 3438 (96.3%) | 3067 (95.9%) | .377 |
| Emergency surgery | 135 (3.8%) | 130 (4.1%) | .572 |
| Multivisceral resection | 257 (7.2%) | 229 (7.2%) | .962 |
| Obstructive colorectal cancer a | 267 (7.5%) | 225 (7.0%) | .512 |
| Chemotherapy or chemoradiotherapy before surgery | 132 (3.7%) | 119 (3.7%) | 1.000 |
Data are the median (range) or number (%) of patients, unless indicated otherwise.
a
Obstructive colorectal cancer included only cases classified as grade III or higher in the Clavien–Dindo classification system; BMI: body mass index; ASA‐PS: American Society of Anesthesiologists‐physical status.
b
P‐values were determined with the Fisher’s exact test.
c
Mann–Whitney test or
d
χ2 test.